Inclusion Criteria:

- Patients with recurrence of invasive epithelial ovarian-, fallopian tube- or primary
peritoneal cancer of any initial stage who have relapsed after a tumor-free interval
of at least 6 months after completion of first-line therapy. The same interval
applies to patients with second relapse who are enrolled after completed
platinum-containing re-induction therapy.

- Women aged > 18 years

- Patients who have given their signed and written informed consent to data
transmission and -processing

Exclusion Criteria:

- Patients with non-epithelial tumors as well as borderline tumors

- Patients who undergo second-look surgery or completion surgery after end of
chemotherapy or during the interval

- Only for the study collective: patients with second malignancies who have been
treated by laparotomy, as well as other neoplasias, if the treatment could interfere
with the treatment of relapsed ovarian cancer

- Patients with a third recurrence

- Patients with so-called platinum-refractory tumor, i.e. progression during
chemotherapy or recurrence within 6 months after end of former platinum-containing
therapy